Abstract: The present invention provides compounds of Formula (I) and (II), or a pharmaceutically acceptable salts thereof, where R53, R54, p, q, and n are as defined herein. The compounds of the present invention have been found to be useful as 17?-hydroxylase/C17,20-lyase inhibitors.
Type:
Grant
Filed:
June 28, 2010
Date of Patent:
September 11, 2012
Assignee:
Novartis AG
Inventors:
Mark G. Bock, Christoph Gaul, Venkateshwar Rao Gummadi, Saumitra Sengupta
Abstract: Novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs) of the formula (I).
Type:
Grant
Filed:
July 8, 2011
Date of Patent:
June 26, 2012
Assignee:
Novartis AG
Inventors:
Mark G. Palermo, Sushil Kumar Sharma, Christopher Sean Straub, Run-Ming Wang, Leigh Zawel, Yanling Zhang, Zhuoliang Chen, Yaping Wang, Fan Yang, Wojciech Wrona, Gang Liu, Mark G. Charest, Feng He
Abstract: Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein
Abstract: Compounds of Formula (IA) that act as 5-HT receptor ligands and their uses in the treatment of diseases linked to the activation of 5-HT2 receptors in animals are described herein.
Type:
Grant
Filed:
May 28, 2002
Date of Patent:
November 30, 2004
Assignee:
Pfizer Inc
Inventors:
Phoebe Chiang, William A. Novomisle, Willard M. Welch, Jr.
Abstract: A method of treating a female suffering from FSD, in particular FSAD, is described. The method comprises delivering to the female an agent that is capable of potentiating cAMP in the sexual genitalia; wherein the agent is in an amount to cause potentiation of cAMP in the sexual genitalia of the female. The agent may be admixed with a pharmaceutically acceptable carrier, diluent or excipient.
Type:
Grant
Filed:
November 8, 2000
Date of Patent:
May 11, 2004
Assignee:
Pfizer Inc.
Inventors:
Graham Nigel Maw, Christopher Peter Wayman
Abstract: The present invention provides a method of treating obesity, sexual dysfunction (including erectile dysfunction), diabetes, insulin resistance, hyperinsulinemia, Syndrome X, adrenal dysfunction, hypertension, hypercholesterolemia, atherosclerosis, hyperlipoproteinemia, hypertriglyceridemia, or substance abuse, the method comprising the step of administering to a patent having or at risk of having one of the above-mentioned diseases a therapeutically effective amount of a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not attenuate the binding of &agr;-melanocyte stimulating hormone to melanocortin receptors.
Abstract: The invention relates to triamide MTP/ApoB inhibitors of the formula 1
wherein R1-R8 are as defined in the specification, as well as pharmaceutical compositions and uses thereof, and processes for preparing the compounds. The compounds of the invention are useful for the treatment of obesity and lipid disorders.
Type:
Grant
Filed:
June 20, 2002
Date of Patent:
April 13, 2004
Assignee:
Pfizer Inc.
Inventors:
Peter Bertinato, Alan E. Blize, Brian S. Bronk, Hengmiao Cheng, Jin Li, Hiep Huatan, Clive Mason
Abstract: The instant invention provides &bgr;3 adrenergic receptor agonists of structural Formula (I),
the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, wherein Ar, R, R1, R2, R3, R4, R5, R6, R7, R8, X, and Y, are as defined herein.
Abstract: A “one-pot” process is described herein for the production of pyrazole compounds of general formula (II)
comprising the steps of reacting a compound of general formula (III)
with an acylating agent in the presence of a base and an optional activating agent followed by the addition of a hydrazine compound in situ.
Type:
Grant
Filed:
January 17, 2003
Date of Patent:
March 2, 2004
Assignee:
Pfizer Inc.
Inventors:
Harris Laurence James, Levett Philip Charles
Abstract: The present invention provides the tosylate salt of (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol, the monohydrate of such salt, processes useful in the preparation of such salt and such monohydrate, pharmaceutical compositions comprising such salt, or such monohydrate, methods of treating &bgr;3-adrenergic receptor-mediated diseases, conditions, and disorders in a mammal using such salt, such monohydrate, or such pharmaceutical compositions; and methods of increasing the content of lean meat in edible animals using such salt, such monohydrate, or such pharmaceutical compositions.
Type:
Grant
Filed:
February 25, 2003
Date of Patent:
February 10, 2004
Assignee:
Pfizer Inc.
Inventors:
Joseph F. Krzyaniak, Jennifer A. Lafontaine
Abstract: The present invention provides processes useful in the preparation of certain &bgr;3-adrenergic receptor agonists of the structural formula
the pharmaceutically acceptable salts thereof, and the hydrates of said pharmaceutically acceptable salts, wherein HET is as described herein. The invention further provides intermediates useful in the preparation of such agonists, and processes useful in the production of such intermediates.
Type:
Grant
Filed:
February 20, 2003
Date of Patent:
February 10, 2004
Assignee:
Pfizer Inc.
Inventors:
Robert J. Chambers, Robert W. Dugger, Ming Kang, Yong Tao, John W. Wong
Abstract: A process for preparing a compound of the formula
wherein n, R1, R2, R3 and X are as defined above, used as an intermediate in the synthesis of &bgr;-adrenergic receptor agonists.
Abstract: Compounds of the formula
are neuropeptide Y antagonists and are effective in treating feeding disorders, cardiovascular diseases and other physiological disorders related to an excess of neuropeptide Y.
Type:
Grant
Filed:
August 21, 2002
Date of Patent:
November 18, 2003
Assignee:
Pfizer Inc.
Inventors:
Richard L. Elliott, Robert M. Oliver, III
Abstract: There is provided compounds of formula IA and of formula IB,
wherein R1, R2, R3, Het1 and X have meanings given in the description, which are useful in the curative and prophylactic treatment of medical conditions for which inhibition of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase (e.g. cGMP PDE5) is desired.
Abstract: There is provided compounds of formula IA and of formula IB,
wherein R1, R2, R3, Het1 and X have meanings given in the description, which are useful in the curative and prophylactic treatment of medical conditions for which inhibition of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase (e.g. cGMP PDE5) is desired.
Abstract: The instant invention provides &bgr;3 adrenergic receptor agonists of structural Formula (I),
the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, wherein Ar, R, R1, R2, R3, R4, R5, R6, R7, R8, X, and Y, are as defined herein.
Abstract: NPY antagonists, methods of using such NPY antagonists and pharmaceutical compositions containing such NPY antagonists. The NPY antagonists are useful for the treatment of NPY mediated disease/conditions including obesity.
Type:
Grant
Filed:
January 4, 2001
Date of Patent:
February 4, 2003
Assignee:
Pfizer Inc.
Inventors:
Richard L. Elliott, Richard F. Hank, Marlys Hammond
Abstract: Compounds of the formula
wherein X is NR4R5, Y is selected from C1-C6 alkyl; alkoxyalkyl, C2-C6 alkenyl; C2-C6 alkynyl, alkoxy, aryl, or heteroaryl, or NR4R5, and R3 is selected from optionally substituted aryl or heteroaryl, optionally substituted, are neuropeptide antagonists and are effective in treating feeding disorders, cardiovascular diseases and other physiological disorders related to an excess of neuropeptide Y.
Abstract: There is provided compounds of formula IA and of formula IB,
wherein R1, R2, R3, Het1 and X have meanings given in the description, which are useful in the curative and prophylactic treatment of medical conditions for which inhibition of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase (e.g. cGMP PDE5) is desired.